Jun 16, 2020
Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer
May 11, 2020
AllianceRx Walgreens Prime studies the use of cyclin-dependent kinase 4/6 inhibitors in breast cancer patients
Sep 29, 2019
Verzenio® (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study
Sep 19, 2019
Lilly Announces Webcast to Discuss ESMO 2019 Presentations
Jul 30, 2019
Lilly's Verzenio® (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2
May 20, 2019
Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology
May 15, 2019
Data Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer
Dec 18, 2018
Lilly announces publication of analyses showing benefit of the addition of Verzenio® (abemaciclib) in multiple subgroups of patients with advanced breast cancer identified as having a more concerning prognosis
Dec 03, 2018
NCCN Oncology Research Program Awarded $2 Million from Lilly to Study Mechanisms of Resistance to CDK4 & 6 Inhibitors in Breast Cancer Treatment
Nov 29, 2018
Lilly to Present Clinical Data for Verzenio® (abemaciclib) and Real-World Evidence across HR+, HER2- Metastatic Breast Cancer at 2018 SABCS
Oct 08, 2018
Lilly to Present New Data From Oncology Portfolio at ESMO 2018 Congress, Showcasing Patient-Centric Advances in Cancer Care
May 16, 2018
Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care
Feb 26, 2018
Lilly Receives Additional FDA Approval for VerzenioTM (abemaciclib), as Initial Treatment for Advanced Breast Cancer
Oct 12, 2017
FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio(TM) (abemaciclib) as Initial Treatment of Advanced Breast Cancer
Oct 10, 2017
Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio(TM) (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer
Oct 10, 2017
Diplomat Selected to Dispense VERZENIO(TM) for Breast Cancer
Oct 06, 2017
Lilly MONARCH 3 Study Published in Journal of Clinical Oncology Demonstrates Benefit of Verzenio(TM) (abemaciclib) Plus NSAI in Advanced Breast Cancer
Sep 05, 2017
MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor
Aug 29, 2017
New Phase 3 Data for Abemaciclib and Ramucirumab Presented at ESMO 2017 Congress
Jun 03, 2017
Lilly Builds Upon Body of Data for Abemaciclib with Phase 3 MONARCH 2 Data Demonstrating Superior Progression-Free Survival in Advanced Breast Cancer